Standard-Volume Is As Effective As High-Volume Plasma Exchange for Patients With Acute Liver Failure
© 2024 Indian National Association for Study of the Liver. Published by Elsevier B.V. All rights reserved..
Background/Aims: Acute liver failure (ALF) is associated with fatal outcomes without liver transplantation. Two randomized studies reported standard volume (SV) and high volume (HV) plasma exchange (PLEX) as effective therapeutic modalities for patients with ALF. However, no studies have compared the safety and efficacy of SV with HV PLEX, which we aimed to assess.
Methods: This retrospective study included patients with ALF admitted between March 2021 and March 2023 who underwent PLEX. All patients underwent HV PLEX until May 2022, and then thereafter, SV PLEX was performed. The objectives of the study were to compare transplant-free survival (TFS) at 30 days, efficacy in reducing severity scores, biochemical variables, and adverse events between SV (total plasma volume x 1) and HV (total plasma volume x 1.5-2) PLEX.
Results: Forty two ALF patients (median age: 23.5 years; females: 57.1%; MELD Na: 34.67 ± 6.07; SOFA score- 5.24 ± 1.42) underwent PLEX. Of these, 22 patients underwent SV-PLEX, and 20 underwent HV-PLEX. The mean age, sex, etiology distribution, and severity scores were similar between the groups. The median number of PLEX sessions (2) was similar in both groups. On Kaplan-Meier analysis, TFS was 45.5% in SV group and 45% in HV group (P = 0.76). A comparable decline in total bilirubin, PT/INR, ammonia, and MELD Na scores was noted in both groups. The cumulative number of adverse events was similar between the HV group (77.3%) and SV group (54.5%; P = 0.12).
Conclusions: SV PLEX is safe and as effective as HV PLEX in patients with ALF. Further randomized controlled trials with a larger sample size are needed to validate these findings.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Journal of clinical and experimental hepatology - 14(2024), 3 vom: 18. Feb., Seite 101354 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kulkarni, Anand V [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Journal Article |
|---|
| Anmerkungen: |
Date Revised 27.02.2024 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.jceh.2024.101354 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368965929 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368965929 | ||
| 003 | DE-627 | ||
| 005 | 20240229165034.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240229s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jceh.2024.101354 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1309.xml |
| 035 | |a (DE-627)NLM368965929 | ||
| 035 | |a (NLM)38406612 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kulkarni, Anand V |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Standard-Volume Is As Effective As High-Volume Plasma Exchange for Patients With Acute Liver Failure |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 27.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2024 Indian National Association for Study of the Liver. Published by Elsevier B.V. All rights reserved. | ||
| 520 | |a Background/Aims: Acute liver failure (ALF) is associated with fatal outcomes without liver transplantation. Two randomized studies reported standard volume (SV) and high volume (HV) plasma exchange (PLEX) as effective therapeutic modalities for patients with ALF. However, no studies have compared the safety and efficacy of SV with HV PLEX, which we aimed to assess | ||
| 520 | |a Methods: This retrospective study included patients with ALF admitted between March 2021 and March 2023 who underwent PLEX. All patients underwent HV PLEX until May 2022, and then thereafter, SV PLEX was performed. The objectives of the study were to compare transplant-free survival (TFS) at 30 days, efficacy in reducing severity scores, biochemical variables, and adverse events between SV (total plasma volume x 1) and HV (total plasma volume x 1.5-2) PLEX | ||
| 520 | |a Results: Forty two ALF patients (median age: 23.5 years; females: 57.1%; MELD Na: 34.67 ± 6.07; SOFA score- 5.24 ± 1.42) underwent PLEX. Of these, 22 patients underwent SV-PLEX, and 20 underwent HV-PLEX. The mean age, sex, etiology distribution, and severity scores were similar between the groups. The median number of PLEX sessions (2) was similar in both groups. On Kaplan-Meier analysis, TFS was 45.5% in SV group and 45% in HV group (P = 0.76). A comparable decline in total bilirubin, PT/INR, ammonia, and MELD Na scores was noted in both groups. The cumulative number of adverse events was similar between the HV group (77.3%) and SV group (54.5%; P = 0.12) | ||
| 520 | |a Conclusions: SV PLEX is safe and as effective as HV PLEX in patients with ALF. Further randomized controlled trials with a larger sample size are needed to validate these findings | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a MELD Na | |
| 650 | 4 | |a liver failure | |
| 650 | 4 | |a liver transplantation | |
| 650 | 4 | |a plasma exchange | |
| 700 | 1 | |a Venishetty, Shantan |e verfasserin |4 aut | |
| 700 | 1 | |a Vora, Moiz |e verfasserin |4 aut | |
| 700 | 1 | |a Naik, Pragati |e verfasserin |4 aut | |
| 700 | 1 | |a Chouhan, Digvijay |e verfasserin |4 aut | |
| 700 | 1 | |a Iyengar, Sowmya |e verfasserin |4 aut | |
| 700 | 1 | |a Karandikar, Puja |e verfasserin |4 aut | |
| 700 | 1 | |a Gupta, Anand |e verfasserin |4 aut | |
| 700 | 1 | |a Gahra, Amrit |e verfasserin |4 aut | |
| 700 | 1 | |a Rakam, Kalyan |e verfasserin |4 aut | |
| 700 | 1 | |a Parthasarthy, Kumaraswamy |e verfasserin |4 aut | |
| 700 | 1 | |a Alla, Manasa |e verfasserin |4 aut | |
| 700 | 1 | |a Sharma, Mithun |e verfasserin |4 aut | |
| 700 | 1 | |a Ramachandra, Sumana |e verfasserin |4 aut | |
| 700 | 1 | |a Menon, Balachandran |e verfasserin |4 aut | |
| 700 | 1 | |a Gupta, Rajesh |e verfasserin |4 aut | |
| 700 | 1 | |a Padaki, Nagaraja R |e verfasserin |4 aut | |
| 700 | 1 | |a Reddy, Duvvu N |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical and experimental hepatology |d 2011 |g 14(2024), 3 vom: 18. Feb., Seite 101354 |w (DE-627)NLM214404560 |x 0973-6883 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2024 |g number:3 |g day:18 |g month:02 |g pages:101354 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jceh.2024.101354 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2024 |e 3 |b 18 |c 02 |h 101354 | ||